Managing Adverse Events and Supportive Care Measures in CLL Treatment

Author(s):

Kirollos Hanna, PharmD, BCPS, BCOP,Brandon Dyson, PharmD, BCPS

The discussion covers proactive strategies and interventions for managing adverse events before dose modification and explores supportive care measures for chronic lymphocytic leukemia treatments, including variations based on specific Bruton tyrosine kinase inhibitors.

EP: 1.BTK Inhibitor-Associated Adverse Events

Now Viewing

EP: 2.Managing Adverse Events and Supportive Care Measures in CLL Treatment

EP: 3.Impact of Dose Modifications on CLL Treatment

EP: 4.Considerations for Dose Modifications

EP: 5.Economic Impact of Dose Modifications on CLL Management

EP: 6.Factors to Consider When Switching Therapies

EP: 7.Medicare Part D Smoothing Program: Impact on Access and Adherence

Video content above is prompted by the following:

What proactive strategies and interventions are used to manage adverse events before resorting to dose modification?
What supportive care measures are typically implemented to manage adverse events in chronic lymphocytic leukemia treatments and do these vary based on the specific Bruton tyrosine kinase inhibitor?